Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KAON CL-10 vs MICRO-K
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium supplement to treat or prevent hypokalemia; potassium is the major intracellular cation essential for nerve transmission, muscle contraction, and acid-base balance.
Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving diuretics or other drugs that deplete potassium
Treatment of hypokalemia,Prevention of hypokalemia in patients at risk (e.g., on diuretics, digitalis)
Oral: 20 m Eq (2 tablets) 2-4 times daily with meals; maximum 100 m Eq/day.
Oral: 20-40 m Eq (1-2 capsules) two to four times daily; maximum 100 m Eq/day. Each capsule contains 8 m Eq (600 mg) of potassium chloride in a wax matrix extended-release formulation.
Terminal elimination half-life is approximately 3-5 hours in healthy adults, reflecting rapid equilibration with the total body potassium pool. Clinically, the half-life is not directly applicable due to extensive intracellular distribution; steady-state is achieved within 24-48 hours.
Not applicable; potassium is an electrolyte with no true elimination half-life; whole-body turnover half-life is approximately 12-24 hours, clinically relevant for dosing intervals.
Potassium is primarily excreted unchanged by the kidneys; metabolism is not significant.
Potassium ions are not metabolized; they are primarily excreted unchanged by the kidneys (90%), with minor losses via feces and sweat.
Primarily renal elimination (>90% as unchanged drug); minor biliary/fecal excretion (<5%). Excretion is via glomerular filtration and tubular reabsorption; potassium excretion is influenced by aldosterone and acid-base status.
Renal: approximately 90% of absorbed potassium is excreted in urine; biliary/fecal: less than 10% eliminated via feces.
Potassium is not significantly protein-bound; <5% bound to plasma proteins.
None; potassium is not significantly bound to plasma proteins.
Approximately 0.5 L/kg, representing distribution primarily into intracellular fluid (98% of total body potassium is intracellular). Clinical meaning: Low Vd indicates limited distribution to extracellular space; high intracellular uptake requires careful dosing to avoid hyperkalemia.
0.5-0.7 L/kg; total body water distribution; clinically indicates extensive intracellular uptake (98% intracellular).
Oral: >90% absorbed via passive diffusion along the gastrointestinal tract. Intravenous: 100% bioavailability.
Oral: approximately 80-90% for Micro-K (extended-release); absorption occurs in small intestine.
GFR 30-50 m L/min: reduce dose by 25%; GFR 10-29 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
e GFR ≥60 m L/min: No adjustment. e GFR 30-59: Reduce dose by 25-50% and monitor potassium. e GFR 15-29: Reduce dose by 50-75% and monitor potassium. e GFR <15: Avoid use or use with extreme caution; maximum 20 m Eq/day with frequent monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use.
No specific dosing adjustments recommended for hepatic impairment. Monitor potassium levels as hepatic disease may affect potassium homeostasis.
Oral: 1-3 m Eq/kg/day in divided doses, maximum 3 m Eq/kg/day; not recommended for children <1 year.
Oral: <1 year: 1-2 m Eq/kg/day divided 2-4 times. 1-18 years: 1-3 m Eq/kg/day divided 2-4 times; maximum 100 m Eq/day. Extended-release capsules not recommended for children unable to swallow whole capsules.
Start at lowest dose (10 m Eq twice daily); monitor renal function and potassium levels; avoid doses exceeding 40 m Eq/day.
Start at low end of dosing range (20-40 m Eq/day) due to decreased renal function; maximum 100 m Eq/day. Monitor renal function and potassium levels closely.
Warning: Potassium chloride can cause hyperkalemia and cardiac arrest if given too rapidly or in excessive doses. Avoid in patients with severe renal impairment, adrenal insufficiency, or concurrent use of potassium-sparing diuretics.
None
Monitor serum potassium levels and renal function; avoid high doses or rapid infusion; use with caution in patients with cardiac disease or receiving digitalis; gastrointestinal irritation may occur with oral preparations.
Hyperkalemia risk, especially in patients with renal impairment, diabetes, or those receiving potassium-sparing diuretics, ACE inhibitors, or ARBs,Suspect gastrointestinal obstruction or perforation with slow-release formulations; caution in patients with severe GI disorders,Use with caution in patients with cardiac disease, particularly those on digoxin,Monitor serum potassium levels regularly
Severe renal impairment (e.g., anuria, oliguria), untreated Addison's disease, hyperkalemia from any cause, acute dehydration, heat cramps, concurrent use of potassium-sparing diuretics (e.g., amiloride, spironolactone), hypersensitivity to potassium chloride.
Hyperkalemia (serum potassium >5.5 m Eq/L),Renal failure or severe renal impairment (e.g., oliguria, anuria),Addison's disease,Acute dehydration,Concomitant use with potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene),Concomitant use with eplerenone,Solid dosage forms in patients with delayed gastric emptying or esophageal compression
Avoid salt substitutes and low-sodium products that contain potassium chloride. No specific food restrictions beyond ensuring adequate water intake with each dose to prevent esophageal or gastric irritation.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes, tomatoes) and potassium-based salt substitutes. Consuming large amounts of these may increase risk of hyperkalemia.
Potassium chloride (the active ingredient in Kaon CL-10) is not associated with teratogenic risk in any trimester. No fetal malformations or developmental toxicity have been reported. Hypokalemia itself may pose maternal and fetal risks, but the drug does not have intrinsic teratogenic potential.
Potassium chloride (Micro-K) is not associated with major congenital malformations. Normal maternal serum potassium levels are required for fetal development. Hypokalemia or hyperkalemia may increase risks. No trimester-specific risks documented.
Potassium chloride is a normal constituent of breast milk. M/P ratio not applicable as potassium is present endogenously. Supplementation to correct maternal hypokalemia is considered safe during breastfeeding, as potassium levels in milk are tightly regulated and maternal supplementation does not significantly alter infant potassium levels.
Potassium is a normal constituent of breast milk. Supplemental potassium does not affect milk potassium content. M/P ratio not applicable. Use with caution if maternal renal function impaired.
No dose adjustment required for pregnancy. Maternal potassium requirements may increase slightly due to increased plasma volume and renal blood flow, but hypokalemia should be corrected per standard guidelines. Monitor serum potassium to avoid hyperkalemia.
No standard dose reduction required. Pharmacokinetic changes in pregnancy (increased GFR, blood volume) may increase potassium requirements or decrease serum levels; monitor and adjust dose to maintain normal serum potassium (3.5-5.0 m Eq/L).
Kaon CL-10 is a solid oral dosage form of potassium chloride (KCl) 10 m Eq. Do not split or crush tablets; they must be swallowed whole with a full glass of water to reduce GI irritation. Monitor serum potassium, renal function, and ECG. Use with caution in patients with impaired renal function or those on ACE inhibitors, ARBs, or potassium-sparing diuretics. Rapid IV correction is reserved for severe hypokalemia with ECG changes.
Micro-K (potassium chloride extended-release) is used to prevent and treat hypokalemia. Avoid use in severe renal impairment, metabolic acidosis, or conditions with high potassium levels. Slow-release formulations reduce GI irritation but may be contraindicated in patients with GI motility disorders. Do not crush or chew capsules; administer with food and a full glass of water. Monitor serum potassium and renal function regularly.
Take this medication with food and a full glass of water to prevent stomach upset.,Do not crush, chew, or split the tablet; swallow it whole.,Missing a dose: take it as soon as you remember unless almost time for the next dose; do not double up.,Report symptoms of high potassium: muscle weakness, tiredness, numbness/tingling, irregular heartbeat, or confusion.,Do not use salt substitutes or potassium-containing supplements unless directed by your doctor.
Take this medication with food and a full glass of water to reduce stomach upset.,Swallow the capsule whole; do not crush, chew, or open it.,Do not suddenly stop taking this medication without consulting your doctor.,Avoid salt substitutes or potassium-containing supplements unless approved by your doctor.,Seek immediate medical attention if you experience signs of high potassium levels: muscle weakness, irregular heartbeat, or tingling in hands/feet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KAON CL-10 vs MICRO-K, answered by our medical review team.
KAON CL-10 is a Electrolyte Supplement (Potassium) that works by Potassium supplement to treat or prevent hypokalemia; potassium is the major intracellular cation essential for nerve transmission, muscle contraction, and acid-base balance.. MICRO-K is a Electrolyte Supplement (Potassium) that works by Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KAON CL-10 and MICRO-K depend on the specific clinical indication. These are both Electrolyte Supplement (Potassium) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KAON CL-10 is: Oral: 20 m Eq (2 tablets) 2-4 times daily with meals; maximum 100 m Eq/day.. The standard adult dose of MICRO-K is: Oral: 20-40 m Eq (1-2 capsules) two to four times daily; maximum 100 m Eq/day. Each capsule contains 8 m Eq (600 mg) of potassium chloride in a wax matrix extended-release formulation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KAON CL-10 and MICRO-K in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KAON CL-10 is classified as Category C. Potassium chloride (the active ingredient in Kaon CL-10) is not associated with teratogenic risk in any trimester. No fetal malformations or developmental toxicity have been report. MICRO-K is classified as Category C. Potassium chloride (Micro-K) is not associated with major congenital malformations. Normal maternal serum potassium levels are required for fetal development. Hypokalemia or hyperk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.